Editas Medicine Inc

For the period ended Sep 30, 2024. Filed Nov 4, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 4, 2024

EDIT$2.51-8.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity for the

Condensed Consolidated Statements of Stockholders’ Equity

(amounts in thousands, except share data)

Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveIncome (Loss) · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount
Balance at December 31, 2023	81,767,263	$8	$1,580,241	$198		$(1,231,350)			$349,097
Exercise of stock options	21,975	—	192	—		—			192
Vesting of restricted common stock awards	445,713	—	—	—		—			—
Stock-based compensation expense	—	—	7,585	—		—			7,585
Unrealized loss on marketable debt securities	—	—	—	(524)		—			(524)
Net loss	—	—	—	—		(61,950)			(61,950)
Balance at March 31, 2024	82,234,951	$8	$1,588,018	$(326)		$(1,293,300)			$294,400
Stock-based compensation expense	—	—	5,010	—		—			5,010
Vesting of restricted common stock awards	121,643	—	—	—		—			—
Issuance of common stock under employee stock purchase plan	72,920	—	322	—		—			322
Unrealized loss on marketable debt securities	—	—	—	(116)		—			(116)
Net loss	—	—	—	—		(67,607)			(67,607)
Balance at June 30, 2024	82,429,514	$8	$1,593,350	$(442)		$(1,360,907)			$232,009
Stock-based compensation expense	—	—	4,802				4,802
Vesting of restricted common stock awards	109,110	—	—				—
Unrealized gain on marketable debt securities	—	—	—	964				964
Net loss	—	—	—		(62,141)			(62,141)
Balance at September 30, 2024	82,538,624	$8	$1,598,152	$522		$(1,423,048)			$175,634

Condensed Consolidated Statements of Stockholders’ Equity

(amounts in thousands, except share data)

Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveLoss · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount
Balance at December 31, 2022	68,847,382	$7		$1,442,405			$(3,601)		$(1,078,131)			$360,680
Vesting of restricted common stock awards	146,209	—		—			—		—			—
Stock-based compensation expense	—	—		4,507			—		—			4,507
Unrealized gain on marketable debt securities	—	—		—			1,322		—			1,322
Net loss	—	—		—			—		(49,036)			(49,036)
Balance at March 31, 2023	68,993,591	$7		$1,446,912			$(2,279)		$(1,127,167)			$317,473
Issuance of common stock from public offering, net commissions, underwriting discounts and offering costs	12,500,000	1		117,078			—		—			117,079
Exercise of stock options	3,122	—		11			—		—			11
Stock-based compensation expense	—	—		5,215			—		—			5,215
Vesting of restricted common stock awards	64,492	—		—			—		—			—
Issuance of common stock under employee stock purchase plan	55,704	—		435			—		—			435
Unrealized loss on marketable debt securities	—	—		—			(6)		—			(6)
Net loss	—	—		—			—		(40,290)			(40,290)
Balance at June 30, 2023	81,616,909	$8		$1,569,651			$(2,285)		$(1,167,457)			$399,917
Vesting of restricted common stock awards	51,887		—							—
Stock-based compensation expense	—		—		4,731						4,731
Unrealized gain on marketable debt securities	—	—				833				833
Net loss	—	—						(45,019)		(45,019)
Balance at September 30, 2023	81,668,796	$8		$1,574,382			$(1,452)		$(1,212,476)			$360,462

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.